In a recent transaction on July 1st, Kristen M. Oelschlager, the Chief Operating Officer of Castle Biosciences Inc (NASDAQ:CSTL), a company specializing in medical laboratories, sold 2,793 shares of the company's common stock. The transaction was executed at varying prices ranging from $20.890 to $21.705, with a weighted-average sale price of $21.224 per share, culminating in a total sale value of $59,278.
This sale was conducted under a prearranged trading plan, known as a Rule 10b5-1 plan, which Oelschlager had adopted on March 15, 2024. Such plans allow company insiders to sell shares over a predetermined period of time, providing a defense against potential claims of insider trading.
Following the sale, Oelschlager's remaining stake in Castle Biosciences consists of 148,618 shares. It is important to note that this figure includes 1,109 shares that were acquired under the company's employee stock purchase plan on February 29, 2024
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.